Posted by Michael Wonder on 25 May 2017
CADTH recommends reimbursement of Gilead's Odefsey
25 May 2017 - The CADTH Canadian Drug Expert Committee has recommended that emtricitabine/rilpivirine/tenofovir alafenamide be reimbursed as a complete regimen for the treatment of adults infected with human immunodeficiency virus type 1 who have no known mutations associated with resistance.
The cost of Odefsey should not exceed the cost of FTC/RPV/tenofovir disoproxil fumarate (TDF) or the individual components of Odefsey used in combination.
